Literature DB >> 30023086

Cetuximab in the treatment of advanced non-small cell lung cancer: FISHing for a miraculous catch.

Lorenza Landi1, Antonio Rossi2.   

Abstract

Entities:  

Year:  2018        PMID： 30023086      PMCID： PMC6036025          DOI： 10.21037/jtd.2018.04.126

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  17 in total

1.  Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.

Authors:  Roy S Herbst; Karen Kelly; Kari Chansky; Philip C Mack; Wilbur A Franklin; Fred R Hirsch; James N Atkins; Shaker R Dakhil; Kathy S Albain; Edward S Kim; Mary Redman; John J Crowley; David R Gandara
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

Review 2.  Epidermal growth factor receptor-directed monoclonal antibodies in nonsmall cell lung cancer: an update.

Authors:  Robert Pirker
Journal:  Curr Opin Oncol       Date:  2015-03       Impact factor: 3.645

3.  Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

Authors:  Nasser Hanna; David Johnson; Sarah Temin; Sherman Baker; Julie Brahmer; Peter M Ellis; Giuseppe Giaccone; Paul J Hesketh; Ishmael Jaiyesimi; Natasha B Leighl; Gregory J Riely; Joan H Schiller; Bryan J Schneider; Thomas J Smith; Joan Tashbar; William A Biermann; Gregory Masters
Journal:  J Clin Oncol       Date:  2017-08-14       Impact factor: 44.544

4.  Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer.

Authors:  Jean-Louis Pujol; Robert Pirker; Thomas J Lynch; Charles A Butts; Rafael Rosell; Frances A Shepherd; Johan Vansteenkiste; Kenneth J O'Byrne; Barbara de Blas; Jim Heighway; Anja von Heydebreck; Nick Thatcher
Journal:  Lung Cancer       Date:  2013-11-16       Impact factor: 5.705

5.  Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.

Authors:  Luis Paz-Ares; Jörg Mezger; Tudor E Ciuleanu; Jürgen R Fischer; Joachim von Pawel; Mariano Provencio; Andrzej Kazarnowicz; György Losonczy; Gilberto de Castro; Aleksandra Szczesna; Lucio Crino; Martin Reck; Rodryg Ramlau; Ernst Ulsperger; Christian Schumann; Jose Elias A Miziara; Álvaro E Lessa; Mircea Dediu; Beatrix Bálint; Henrik Depenbrock; Victoria Soldatenkova; Raffael Kurek; Fred R Hirsch; Nick Thatcher; Mark A Socinski
Journal:  Lancet Oncol       Date:  2015-02-18       Impact factor: 41.316

6.  Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung.

Authors:  V Rusch; J Baselga; C Cordon-Cardo; J Orazem; M Zaman; S Hoda; J McIntosh; J Kurie; E Dmitrovsky
Journal:  Cancer Res       Date:  1993-05-15       Impact factor: 12.701

7.  Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.

Authors:  Roy S Herbst; Mary W Redman; Edward S Kim; Thomas J Semrad; Lyudmila Bazhenova; Gregory Masters; Kurt Oettel; Perry Guaglianone; Christopher Reynolds; Anand Karnad; Susanne M Arnold; Marileila Varella-Garcia; James Moon; Philip C Mack; Charles D Blanke; Fred R Hirsch; Karen Kelly; David R Gandara
Journal:  Lancet Oncol       Date:  2017-11-20       Impact factor: 41.316

8.  Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

Authors:  Robert Pirker; Jose R Pereira; Aleksandra Szczesna; Joachim von Pawel; Maciej Krzakowski; Rodryg Ramlau; Ihor Vynnychenko; Keunchil Park; Chih-Teng Yu; Valentyn Ganul; Jae-Kyung Roh; Emilio Bajetta; Kenneth O'Byrne; Filippo de Marinis; Wilfried Eberhardt; Thomas Goddemeier; Michael Emig; Ulrich Gatzemeier
Journal:  Lancet       Date:  2009-05-02       Impact factor: 79.321

9.  Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536.

Authors:  Edward S Kim; James Moon; Roy S Herbst; Mary W Redman; Shaker R Dakhil; Mario R Velasco; Fred R Hirsch; Philip C Mack; Karen Kelly; John V Heymach; David R Gandara
Journal:  J Thorac Oncol       Date:  2013-12       Impact factor: 15.609

10.  Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.

Authors:  Shirin Khambata-Ford; Christopher T Harbison; Lowell L Hart; Melissa Awad; Li-An Xu; Christine E Horak; Shaker Dakhil; Robert C Hermann; Thomas J Lynch; Martin R Weber
Journal:  J Clin Oncol       Date:  2010-01-25       Impact factor: 44.544
View more
  1 in total

1.  Oral Squamous Cell Carcinoma in Young Patients Show Higher Rates of EGFR Amplification: Implications for Novel Personalized Therapy.

Authors:  Laveniya Satgunaseelan; Sean Porazinski; Dario Strbenac; Aji Istadi; Cali Willet; Tracy Chew; Rosemarie Sadsad; Carsten E Palme; Jenny H Lee; Michael Boyer; Jean Y H Yang; Jonathan R Clark; Marina Pajic; Ruta Gupta
Journal:  Front Oncol       Date:  2021-11-29       Impact factor: 6.244
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.